Rheumatologists Anticipate IIM Pipeline Advancements
Inadequate disease control remains a persistent challenge in the management of idiopathic inflammatory myopathies (IIM), particularly for dermatomyositis (DM)...
Paragonix LiverGuard System Reduces Post-Transplant Complications
A propensity-matched analysis of 410 liver transplant patients from the GUARDIAN-Liver Registry showed a 51% reduction in early allograft...
Pharmala, Merhavim Center Partner on MDMA Clinical Trial Data
PharmAla Biotech has delivered over 500 capsules of its LaNeo 40mg MDMA to the Merhavim Mental Health Centre in...
Poltreg Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes
PolTREG has dosed the first patient in a Phase 2 trial of PTG-007, an autologous cell therapy for pre-symptomatic...
Sonnet Biotherapeutics Expands Ovarian Cancer Dose Escalation Trial
Sonnet BioTherapeutics reports two out of three patients with platinum-resistant ovarian cancer (PROC) achieved a partial response (PR) in...
Clearmind Medicine Gets IRB Approval for Alcohol Use Disorder Trial
Clearmind Medicine has received Institutional Review Board (IRB) approval from Hadassah Medical Center in Jerusalem for its ongoing Phase...
Aptose Begins 160 mg Tuspetinib Dosing in Tuscany Trial
Aptose Biosciences’ Phase 1/2 TUSCANY trial of tuspetinib (TUS) in combination with venetoclax and azacitidine (VEN/AZA) has cleared the...
Distalmotion Enrolls Dexter® System Trials for Surgery and Gynecology
Distalmotion has reached key enrollment milestones in two US pivotal trials for its DEXTER robotic surgery system: RAVEN for...
Arch Biopartners Doses First Patient in LSALT Peptide Trial
Arch Biopartners has dosed the first patient at Toronto General Hospital in its Phase 2 trial of LSALT peptide...
Navigating AI in Clinical Trials: Insights from Advarra’s Laura Russell
Advarra has launched the Council for Responsible AI in Clinical Trials to ensure the ethical use of AI in...